For research use only. Not for therapeutic Use.
Toremifene Citrate is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.<br>Toremifene (7.5 mM) causes approximately 60% of the cells to exhibit morphologic characteristics typical of cells undergoing programmed death, or apoptosis in human breast cancer cells. Toremifene (5-10 mM) results in elevated levels of TRPM-2 and TGF beta 1 mRNAs in in vitro or in vivo grown tumor cells. Toremifene causes growth inhibition of estrogen-sensitive breast cancer cells by inducing some cells to undergo apoptosis and by inhibiting other cells from entering mitosis.<br>Toremifene, at the highest tested dose, increases the incidence of hepatocellular carcinomas in the DEN-initiated groups to a level one-third that observed with Tamoxifen administration to DEN-initiated rats. Toremifene increases the incidence of hypernephromas in previously DEN-initiated rats.
| Catalog Number | A001055 |
| CAS Number | 89778-27-8 |
| Synonyms | NSC 613680 |
| Molecular Formula | C26H28ClNO • C6H8O7 |
| Purity | ≥95% |
| Target | Estrogen/progestogen Receptor |
| Solubility | >24.2mg/mL in DMSO |
| Storage | 3 years -20C powder |
| InChIKey | IWEQQRMGNVVKQW-OQKDUQJOSA-N |
